Skip to main content

Lois Shepherd, MDCM, FRCP(C)

Canadian Cancer Trials Group Senior Investigator

Dr. Shepherd is a Professor in the Department of Pathology & Molecular Medicine. She completed her medical school training at McGill and spent three years in England where her interest in hematology developed. She completed her training as a Hematopathologist at the University of Ottawa and came to Kingston in 1987. Dr. Shepherd was the Director of the Transfusion and Immunology Service at Kingston General Hospital until 2016. She now spends her time exclusively with the Canadian Cancer Trials Group (CCTG) having worked with the group since 1989 as a Senior Investigator. Her focus has been in Haematology and Breast Cancer, correlative studies in clinical trials, as well as the development of the National Tumor Tissue Repository at CCTG.

Areas of expertise: hematology, breast cancer, tumour an tissue biorepository and biobanking, correlative studies in clinical trials

Current trials: ALC4, ALC5, ALC6, CX5, MA36, MA.37, MAC18, MAC19, MAC20, MAC21, MAC22, MAC23, MAC24, MAC25, MAC26, LY12, LY17, LY.18, HDC1, HD11, SC26

Selected Publications:

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793-1802, 2003.

Burnell M, Levine MN, Chapman J-AW, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28: 77-82, 2010.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. N Engl J Med 366: 399-408, 2012.

Crump M, Kuruvilla J, Couban S, Macdonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 Journal of Clinical Oncology: 32 (31): 3490 - 3496, 2014

Bosch M, Akhter A, Chen BE, Mansoor A, LeBrun D, Good D, Crump M, Shepherd L, Scott DW, Stewart DA. A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. Haematologica 103: 288-96, 2018.

For a full list of publications please visit PubMed.